ArticleBMC genomics2010
Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.
Article in BMC genomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 65 citations in OpenAlex.
- NSCLC Extracellular Vesicles Containing miR-374a-5p Promote Leptomeningeal Metastasis by Influencing Blood‒Brain Barrier Permeability.Molecular cancer research : MCR · 2024Article
- RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing.Nature communications · 2023Article
- Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer.Human genomics · 2023Article
- A new molecular subclassification andFrontiers in pharmacology · 2023Article
- QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer.Journal of molecular cell biology · 2021Article
- The role of NUMB/NUMB isoforms in cancer stem cells.BMB reports · 2021Review
- Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.International journal of molecular sciences · 2021Review
- Alterations of RNA splicing patterns in esophagus squamous cell carcinoma.Cell & bioscience · 2021Article
- Identification and validation of critical alternative splicing events and splicing factors in gastric cancer progression.Journal of cellular and molecular medicine · 2020Article
- Systematic profiling of alternative splicing signature reveals prognostic predictor for prostate cancer.Cancer science · 2020Article
- Discrete functional and mechanistic roles of chromodomain Y-like 2 (CDYL2) transcript variants in breast cancer growth and metastasis.Theranostics · 2020Article
- High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome.Oncogene · 2019Article
- Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression.Biochimica et biophysica acta. Molecular cell research · 2019Article
- A Review on Adducin from Functional to Pathological Mechanisms: Future Direction in Cancer.BioMed research international · 2018Review
- Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.Cancer cell · 2017Article
- Adducin in tumorigenesis and metastasis.Oncotarget · 2017Review
- Tropomyosin-1 acts as a potential tumor suppressor in human oral squamous cell carcinoma.PloS one · 2017Article
- A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.Molecular oncology · 2016Article
- A proteogenomic approach to understand splice isoform functions through sequence and expression-based computational modeling.Briefings in bioinformatics · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of non-small cell lung cancer with novel targeted therapies is a major unmet clinical need. Alternative splicing is a mechanism which generates diverse protein products and is of functional relevance in cancer.
resultsIn this study, a genome-wide analysis of the alteration of splicing patterns between lung cancer and normal lung tissue was performed. We generated an exon array data set derived from matched pairs of lung cancer and normal lung tissue including both the adenocarcinoma and the squamous cell carcinoma subtypes. An enhanced workflow was developed to reliably detect differential splicing in an exon array data set. In total, 330 genes were found to be differentially spliced in non-small cell lung cancer compared to normal lung tissue. Microarray findings were validated with independent laboratory methods for CLSTN1, FN1, KIAA1217, MYO18A, NCOR2, NUMB, SLK, SYNE2, TPM1, (in total, 10 events) and ADD3, which was analysed in depth. We achieved a high validation rate of 69%. Evidence was found that the activity of FOX2, the splicing factor shown to cause cancer-specific splicing patterns in breast and ovarian cancer, is not altered at the transcript level in several cancer types including lung cancer.
conclusionsThis study demonstrates how alternatively spliced genes can reliably be identified in a cancer data set. Our findings underline that key processes of cancer progression in NSCLC are affected by alternative splicing, which can be exploited in the search for novel targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.